Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer

Cell Genesys

Status and phase: Completed; Phase 2; Phase 1

Conditions: Prostate Cancer

Treatments: Biological: CV787 (CG7870)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00116155

CV787-9902

Details and patient eligibility

About

This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer. Patients will receive treatment intravenously at one of up to nine dose levels, each containing three to six patients.

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)